Navigation Links
Einstein researcher receives $10.8 million grant to study toxic blood reactions caused by hemoglobin

September 17, 2012 (BRONX, NY) The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, has awarded nearly $11 million to Albert Einstein College of Medicine of Yeshiva University to carry out a five-year multi-institutional study of hemoglobin toxicity that may complicate blood transfusions and reduce the effectiveness of blood substitutes. The long-term goals include making blood transfusions safer and more effective and better matching patients with the transfusion strategy best suited to them.

The research is especially important due to the explosion of obesity, diabetes and metabolic syndrome, which increases inflammation in blood vessels and can lead to transfusion complications.

The $10.8 million program project grant will be overseen by the principle investigator, Einstein's Joel Friedman, M.D., Ph.D. , who holds the Young Men's Division Chair in Physiology and is professor of physiology & biophysics and of medicine. The grant will fund research projects at Einstein, Rice University, the University of California, San Diego and the United States Food and Drug Administration (FDA), directed by Dr. Friedman, John Olson, Ph.D., Marcos Intaglietta, Ph.D., and Abdu Alayash, Ph.D., respectively.

The grant focuses on the study of hemoglobin, the protein that gives red blood cells their color. Red cells transport oxygen throughout the body and deliver it to cells. Hemoglobin normally stays inside red blood cells. But under some conditionsincluding sickle cell anemia and transfusions involving stored bloodred cells break open, or lyse, causing substantial amounts of hemoglobin to become acellular (i.e., still in the bloodstream but no longer inside red cells).

Acellular hemoglobin can initiate toxic chemical reactions and processes. This toxicity can trigger or worsen potentially serious inflammation of blood vessels that can complicate blood transfusions and has hampered development of blood substitutes.

The researchers will use the federal grant to determine the mechanisms responsible for making acellular hemoglobin toxic and to develop strategies for preventing, reducing or even reversing toxicity.

Dr. Friedman has brought together teams from Einstein, Rice, UC San Diego and the FDA to take different but complementary research approaches. Dr. Friedman and his Einstein colleagues, including Parimala Nacharaju, Ph.D. , instructor in physiology & biophysics, will study several possible strategies for neutralizing acellular hemoglobin toxicity, including the novel use of nanoparticles that release nitric oxide gas. These particles were developed at Einstein to counteract the role played by acellular hemoglobin in reducing nitric oxide levels.

The Rice/FDA team will evaluate strategies for limiting the toxic consequences of acellular hemoglobin, which include hypertension caused by reduced nitric oxide levels and damage to blood vessel walls caused by harmful chemicals called free radicals. The UC San Diego team, which includes Amy Tsai, Ph.D., and Pedro Cabrales, Ph.D., will conduct animal testing to discover the mechanisms responsible for hemoglobin-based toxicities and develop ways to reduce or eliminate them.

Contact: Kim Newman
Albert Einstein College of Medicine

Related biology news :

1. Researchers find our inner reptile hearts
2. Researchers develop rapid method to measure carbon footprints
3. Rockefeller Universitys Pearl Meister Greengard Prize to be awarded to RNA researcher Joan Steitz
4. Researchers reveal a chemo-resistant cancer stem cell as cancers Achilles heel
5. Researchers use banker plants to help battle whitefly pests
6. Researchers find first evidence for a genetic cause for Barretts oesophagus
7. CIRM funds 6 UC San Diego stem cell researchers
8. Rice University researchers optimize photoluminescent probes to study DNA and more
9. Researchers identify biochemical functions for most of the human genome
10. Georgetown Lombardi researcher awarded Provocative Question grant from NCI
11. NIH-funded researchers restore sense of smell in mice using genetic technique
Post Your Comments:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between the ... has been formalized with the signing of a Memorandum of Understanding. , AMA ... Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
Breaking Biology Technology: